Cargando…
Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?
Multiple myeloma (MM) has emerged as the next most likely oncological or hematological disease indication amenable for cellular immunotherapy. Much of the attention has been focused on B cell maturation antigen (BCMA) as a unique cell surface protein on myeloma cells that is available for monoclonal...
Autores principales: | Xu, Shengli, Lam, Kong-Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226350/ https://www.ncbi.nlm.nih.gov/pubmed/32340409 http://dx.doi.org/10.3390/cancers12041045 |
Ejemplares similares
-
TACI and BAFF-R mediate isotype switching in B cells
por: Castigli, Emanuela, et al.
Publicado: (2005) -
Yet another hump for CAML: support of cell survival independent of tail-anchored protein insertion
por: Shing, Jennifer C, et al.
Publicado: (2017) -
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023) -
CAML regulates Bim-dependent thymocyte death
por: Edgar, Contessa E., et al.
Publicado: (2010) -
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
por: Tai, Yu-Tzu, et al.
Publicado: (2018)